Horizon Europe is a huge innovation funding programme. The subprogrammes have lot's of generic aspects in common, and best practises to take into account.
When applying for a project, you need to take into account the administrative & financial framework, with rules for application and project implementation.
In this part, the European Commission is looking for projects and solutions that can solve current and future global challenges. This is therefore all about how Research and Innovation can improve our society. It is divided in 6 clusters (domains) which in turn are split up in destinations (areas) which again are divided in sections and calls for proposals.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.